Breaking Finance News

Cepheid (NASDAQ:CPHD) has been upgraded to Hold in a statement by TheStreet earlier today.

Having a price of $52.73, Cepheid (NASDAQ:CPHD) traded -0.08% lower on the day. With the last close up 51.67% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CPHD has recorded a 50-day average of $44.63 and a two hundred day average of $34.74. Trade Volume was down over the average, with 1,819,329 shares of CPHD changing hands under the typical 1,875,790

TheStreet has upgraded Cepheid (NASDAQ:CPHD) to Hold in a statement released on Wednesday September 28, 2016.

On 9/12/2016, Robert W. Baird released a statement on Cepheid (NASDAQ:CPHD) maintained the target price at $53.00 that suggested an upside of 0.01%.

Recent Performance Chart


Cepheid has 52 week low of $25.09 and a 52 week high of $53.91 and has a market cap of $0.

In addition to TheStreet reporting its target price, a total of 17 brokers have issued a report on the stock. The consensus target price is $39.50 with 6 brokers rating the stock a strong buy, 5 brokers rating the stock a buy, 10 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Cepheid (NASDAQ:CPHD)

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *